Featured Studies Results
Study Type: Treatment | Keyword: BRCA1
Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
Clinicaltrials.gov identifier:
NCT06545942
Treatment
Treatment study for people with advanced or metastatic cancers
NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer
Clinicaltrials.gov identifier:
NCT05498272
Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations
Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
Clinicaltrials.gov identifier:
NCT04090567
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
Studying the Effectiveness of New PARP Inhibitor, Saruparib Compared to Current Treatment Options for Metastatic Prostate Cancer EvoPAR-PRO1
Clinicaltrials.gov identifier:
NCT06120491
Treatment
Treatment study for metastatic, castration-sensitive prostate cancer
Treating Metastatic BRCA1, BRCA2 or PALB2 Pancreatic Cancer Using a New Combination of Chemotherapy Drugs
Clinicaltrials.gov identifier:
NCT06115499
Treatment
Treatment study for people with metastatic pancreatic cancer and a BRCA1, BRCA2 or PALB2 mutation
Study of the Drug Sovilnesib in People with Ovarian Cancer
Clinicaltrials.gov identifier:
NCT06084416
Treatment
Treatment study for people with platinum-resistant ovarian cancer
Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Clinicaltrials.gov identifier:
NCT05806515
Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Clinicaltrials.gov identifier:
NCT04030559
Treatment
High-risk localized prostate cancer
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
Clinicaltrials.gov identifier:
NCT04550494
Treatment
Treatment study for people with advanced solid tumors
Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation
Clinicaltrials.gov identifier:
NCT04858334
Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
Clinicaltrials.gov identifier:
NCT04038502
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
Clinicaltrials.gov identifier:
NCT04150042
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
Clinicaltrials.gov identifier:
NCT04644068
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation
Clinicaltrials.gov identifier:
NCT04548752
Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
Clinicaltrials.gov identifier:
NCT03990896
Treatment
This is a study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy
If you would like a more in-depth search, visit our In-Depth Search Tool that searches for studies in FORCE’s database and in clinicaltrials.gov
Sponsored By
